Artificial intelligence (AI) is becoming increasingly relevant to antibody discovery and immunotherapy development, supporting target identification, de novo antibody design, antibody engineering, clinical intelligence, and bioprocessing. Advances in generative AI, protein language models, diffusion models, and structure-based models are expanding the use of AI across antibody development, while clinical applications are supporting biomarker discovery, patient stratification, and treatment response prediction.

This analysis examines how AI is shaping synthetic antibody and immunotherapy development across antibody design and engineering, clinical intelligence, bioprocessing and manufacturing, and antibody data platforms. It also evaluates technology maturity, clinical studies, patent activity, funding, partnerships, mergers, acquisitions, competitive developments, and emerging growth opportunities.

• Why are current clinical applications largely focused on optimizing established immunotherapies, and how can AI-designed antibody candidates progress through human clinical development?
• What is the growth potential of de novo antibody design, multi-specific and T cell engager antibodies, and AI-enabled immune profiling and response optimization for antibody-based immunotherapies?
• Which best practices can help your organization harness key areas for future growth?